Risk Management

ROP Injection to Treat

Click on the links below to access the forms.

Consent: ROP Injection to Treat 

Spanish Translation TBD

AntiVEGF for ROP Risk Management Recommendations

Articles on neurodevelopment after Avastin (bevacizumab) injection

OMIC and our ROP Task Force want to let you know of some studies on the effect of Avastin on the infant’s neurodevelopment. We have revised our ROP consent forms to address this research.

Pediatrics published a report[1] showing that the odds of severe neurodevelopmental disabilities was 3.1 times higher in infants treated with Avastin than those treated with laser. Another article[2] showed increased odds only in infants treated with both Avastin and laser.

Research is ongoing to determine if Avastin and other anti-VEGF drugs are safe. In the meantime, we all have to explain what we do know about these drugs to parents whose infants need treatment for ROP.


Please contact our confidential Risk Management Hotline if you need help developing or revising your protocols. You may email us at riskmanagement@omic.com or call 800-562-6642, option 4.



[1] Warren J, Luu TM, Superstein R, et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016; 137 (4): e20153218. http://pediatrics.aappublications.org/content/early/2016/03/16/peds.2015-3218

2 Lien R, Yu M-H, Hsu K-H, Liao P-J, Chen Y-P, Lai C-C, et al. (2016) Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PLoS ONE 11(1): e0148019. doi:10.1371/journal.pone.0148019. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0148019



Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.